Nuclear factor-kappa beta pathway and endometrial cancer: a pilot study

Basit Öğe Kaydı
dc.authoridGül, Mehmet/0000-0002-1374-0783
dc.authoridCOSKUN, Ebru INCI/0000-0003-4402-3725
dc.authorwosidGül, Mehmet/ABI-6336-2020
dc.authorwosidSimsek, Yavuz/AAH-9894-2021
dc.authorwosidTuncay, Görkem/ABI-6418-2020
dc.authorwosidCOSKUN, Ebru INCI/ABI-8238-2020
dc.contributor.authorYilmaz, E.
dc.contributor.authorCoskun, E. I.
dc.contributor.authorGul, M.
dc.contributor.authorSahin, N.
dc.contributor.authorTuncay, G.
dc.contributor.authorSimsek, Y.
dc.date.accessioned2024-08-04T20:44:08Z
dc.date.available2024-08-04T20:44:08Z
dc.date.issued2017
dc.departmentİnönü Üniversitesien_US
dc.description.abstractObjective: Examination of the role of nuclear factor-kappa beta (NF-kappa B) expression in the etiopathogenesis of endometrial cancer, by means of the immunohistochemical method. Materials and Methods: Patients who applied to participate in the study at the clinic were grouped into three categories: those diagnosed with benign endometrial pathology, those with endometrial hyperplasia, and those with endometrial cancer. NF-kappa B analysis was conducted in the endometrial tissues of the patients' paraffin blocks by means of the immunohistochemical method. For objective assessment purposes, the H score of each patient was calculated. SP SS 15.0 program was employed for statistical analysis. Results: The average H score of the first group, comprising benign endometrial pathologies, was 102.4 +/- 85.9, that of the hyperplasia group was 143.6 +/- 122.4, and that of the cancer group was 276.8 +/- 61.8. The average values of groups 1 and 2 were similar (p = 0.349); however, the third group's average H score was significantly higher (p < 0.001). Conclusion: NF-kappa B, which is a critical mediator in the inflammation process, might be related to the development of premalign and malign endometrial changes.en_US
dc.identifier.doi10.12892/ejgo3471.2017
dc.identifier.endpage540en_US
dc.identifier.issn0392-2936
dc.identifier.issue4en_US
dc.identifier.scopus2-s2.0-85037091910en_US
dc.identifier.scopusqualityN/Aen_US
dc.identifier.startpage536en_US
dc.identifier.urihttps://doi.org/10.12892/ejgo3471.2017
dc.identifier.urihttps://hdl.handle.net/11616/98058
dc.identifier.volume38en_US
dc.identifier.wosWOS:000406893500009en_US
dc.identifier.wosqualityQ4en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.language.isoenen_US
dc.publisherI R O G Canada, Incen_US
dc.relation.ispartofEuropean Journal of Gynaecological Oncologyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectEndometrial canceren_US
dc.subjectEndometrial hyperplasiaen_US
dc.subjectInflammationen_US
dc.subjectNF-kBen_US
dc.titleNuclear factor-kappa beta pathway and endometrial cancer: a pilot studyen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu